[
  {
    "ts": "2026-02-23T10:30:00+00:00",
    "headline": "3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds",
    "summary": "Viking stock has plenty of room to run.",
    "url": "https://www.fool.com/investing/2026/02/23/3-reasons-viking-therapeutics-stock-could-10x/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "9dabe636-10b2-3921-929f-f0971dee2050",
      "content": {
        "id": "9dabe636-10b2-3921-929f-f0971dee2050",
        "contentType": "STORY",
        "title": "3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds",
        "description": "",
        "summary": "Viking stock has plenty of room to run.",
        "pubDate": "2026-02-23T10:30:00Z",
        "displayTime": "2026-02-23T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/40166dc06a1cc3bf0520a3b3dc811c96",
          "originalWidth": 1400,
          "originalHeight": 923,
          "caption": "A researcher works at a laptop in a lab.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8ms0ndEUmtXrFkkoECWj0w--~B/aD05MjM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/40166dc06a1cc3bf0520a3b3dc811c96.cf.webp",
              "width": 1400,
              "height": 923,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6DyizSm4MwCeb5llJR76Lg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/40166dc06a1cc3bf0520a3b3dc811c96.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/3-reasons-viking-therapeutics-stock-could-10x/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-viking-therapeutics-stock-103000062.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T10:11:20+00:00",
    "headline": "Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial",
    "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk said on Monday its next-generation obesity drug CagriSema ‌was less effective than Eli Lilly's tirzepatide ‌in a head-to-head trial, a setback in the race ​for dominance in the weight-loss drug market. The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight, but ‌failed to meet ⁠that goal, Novo said in a statement.",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
      "content": {
        "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
        "contentType": "STORY",
        "title": "Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial",
        "description": "",
        "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk said on Monday its next-generation obesity drug CagriSema ‌was less effective than Eli Lilly's tirzepatide ‌in a head-to-head trial, a setback in the race ​for dominance in the weight-loss drug market. The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight, but ‌failed to meet ⁠that goal, Novo said in a statement.",
        "pubDate": "2026-02-23T10:11:20Z",
        "displayTime": "2026-02-23T10:11:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7",
          "originalWidth": 800,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oBGYgL02vdNB3H_4k.SyNw--~B/aD01NzI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 800,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yW1zE99MZUHRvddOxzpIIg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]